Physician profile
Neelima Marpu
NPI 1326116625
$1,549.09
in general payments reported to CMS, 2019-2025
15 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $75.46 · 2021: $314 · 2022: $348 · 2023: $380 · 2024: $48.22 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $482.02 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $280.93 | 2020-2024 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.51 | 2019-2023 | Tradjenta, Jardiance |
| Pfizer INC. | $151.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $108.52 | 2019 | |
| Lilly USA, LLC | $76.24 | 2021-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $63.17 | 2020-2023 | Freestyle Libre 3 |
| Genentech USA, INC. | $55.37 | 2019-2021 | |
| Myriad Women'S Health, INC. | $40.27 | 2023 | Myrisk |
| Takeda Pharmaceuticals U.S.A., INC. | $39.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.15 | 2022 | |
| Medtronic, INC. | $18.02 | 2025 | Inceptiv |
| Jazz Pharmaceuticals INC. | $17.47 | 2022 | |
| Dynavax Technologies Corporation | $12.88 | 2023 | Heplisav-B |
| Arbor Pharmaceuticals, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neelima Marpu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.